GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » Cyclically Adjusted PB Ratio

Cerus (CERS) Cyclically Adjusted PB Ratio : 2.48 (As of Apr. 27, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Cerus Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Cerus's current share price is $1.71. Cerus's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.69. Cerus's Cyclically Adjusted PB Ratio for today is 2.48.

The historical rank and industry rank for Cerus's Cyclically Adjusted PB Ratio or its related term are showing as below:

CERS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.81   Med: 5.93   Max: 13.89
Current: 2.49

During the past years, Cerus's highest Cyclically Adjusted PB Ratio was 13.89. The lowest was 1.81. And the median was 5.93.

CERS's Cyclically Adjusted PB Ratio is ranked worse than
56.14% of 456 companies
in the Medical Devices & Instruments industry
Industry Median: 2.11 vs CERS: 2.49

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cerus's adjusted book value per share data for the three months ended in Dec. 2023 was $0.290. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.69 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cerus Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cerus's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Cyclically Adjusted PB Ratio Chart

Cerus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.74 11.50 10.06 5.04 3.14

Cerus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.04 4.14 3.48 2.31 3.14

Competitive Comparison of Cerus's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, Cerus's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerus's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cerus's Cyclically Adjusted PB Ratio falls into.



Cerus Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cerus's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.71/0.69
=2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cerus's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Cerus's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.29/129.4194*129.4194
=0.290

Current CPI (Dec. 2023) = 129.4194.

Cerus Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.620 99.695 0.805
201406 0.597 100.560 0.768
201409 0.604 100.428 0.778
201412 0.516 99.070 0.674
201503 1.152 99.621 1.497
201506 1.142 100.684 1.468
201509 0.983 100.392 1.267
201512 0.956 99.792 1.240
201603 0.824 100.470 1.061
201606 0.727 101.688 0.925
201609 0.699 101.861 0.888
201612 0.558 101.863 0.709
201703 0.400 102.862 0.503
201706 0.360 103.349 0.451
201709 0.331 104.136 0.411
201712 0.337 104.011 0.419
201803 0.655 105.290 0.805
201806 0.676 106.317 0.823
201809 0.677 106.507 0.823
201812 0.618 105.998 0.755
201903 0.504 107.251 0.608
201906 0.469 108.070 0.562
201909 0.428 108.329 0.511
201912 0.395 108.420 0.472
202003 0.686 108.902 0.815
202006 0.690 108.767 0.821
202009 0.654 109.815 0.771
202012 0.617 109.897 0.727
202103 0.542 111.754 0.628
202106 0.491 114.631 0.554
202109 0.465 115.734 0.520
202112 0.487 117.630 0.536
202203 0.449 121.301 0.479
202206 0.428 125.017 0.443
202209 0.412 125.227 0.426
202212 0.381 125.222 0.394
202303 0.325 127.348 0.330
202306 0.281 128.729 0.283
202309 0.266 129.860 0.265
202312 0.290 129.419 0.290

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cerus  (NAS:CERS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cerus Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cerus's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerus (CERS) Business Description

Traded in Other Exchanges
Address
1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Executives
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Ann Lucena director C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Gail Schulze director 3451 WELLS ROAD, MALVERN PA 19355
Laurence M Corash director C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
William Mariner Greenman officer: President, Cerus Europe C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Chrystal Menard officer: Chief Legal Officer C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Kevin Dennis Green officer: Chief Accounting Officer C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin officer: Chief Medical Officer 15 WHITE PINE ROAD, NEWTON MA 02464
Vivek K Jayaraman officer: Chief Commercial Officer 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Hua Shan director C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Carol Moore officer: SR. V.P. Regulatory, Clinical C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Timothy B Anderson director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451